Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months

Trecia A. Wouldes, Lianne J. Woodward

1 Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand, 2 School of Health Sciences, University of Canterbury, Christchurch, New Zealand

Abstract

The abuse of prescription opioids and heroin by women of childbearing age over the past decade has resulted in a five-fold increase in the number of infants born opioid-dependent. Daily opioid substitution treatment with methadone is associated with less maternal illicit opioid use and improved antenatal care. However, research on the neurobehavioral effects of daily prenatal exposure to methadone on the infant is limited. Using the NICU Network Neurobehavioral Scale (NNNS), we compared the neurobehavior at birth of 86 infants born to opioid-dependent mothers receiving methadone treatment (MMT) with 103 infants unexposed to methadone. Generalized linear models, adjusted for covariates, showed methadone-exposed infants had significantly poorer attention, regulation, and quality of movement. They were also significantly more excitable, more easily aroused, exhibited more non-optimal reflexes, hypertonicity, and total signs of stress abstinence. Maternal MMT was also associated with more indices of neonatal abstinence, including: CNS, visual, genitourinary (GI), and state. Latent profile analysis of the NNNS summary scores revealed four distinct neurobehavioral profiles with infants characterized by the most disturbed neurobehavior at birth having the poorest clinical outcomes at birth, and poorer cognitive and motor development at 24 months of age.

Introduction

Globally, illicit opioids are the most harmful drug to human health [1]. Opioid use is associated with an increased risk of fatal and non-fatal overdoses, as well as infectious diseases such as HIV and Hepatitis C. As a result, opioids account for 12 million disability adjusted life years or 70% of the global burden of drug-related disabilities and deaths. This trend is most prominent in the United States, where opioid-related deaths increased threefold between 1999 and 2015 [1, 2].
Alongside these global trends, there has been a corresponding increase in the use and abuse of prescription opioids, and more recently, heroin, in women of childbearing age [2–4]. This has, in turn, given rise to a three-fold increase in the rate of neonatal abstinence syndrome (NAS) from 2000 to 2009, increasing to a five-fold increase in NAS or neonatal opioid withdrawal syndrome (NOWS) between 2009 and 2012 [5–12]. Typically, the signs of opioid withdrawal include evidence of central nervous system (CNS) irritability, gastrointestinal dysfunction, yawning, sneezing, and fever. Behaviorally, opioid abstinent babies frantically suck their fingers, display incessant and inconsolable high-pitched crying, and are restless and irritable [5–9]. Most of these signs of withdrawal will disappear over the first few months of postnatal life, but CNS disturbance can persist for up to 4 to 6 months [9]. As a result, a significant number of these infants may require extended neonatal intensive care and pharmacotherapy after birth [13].

Daily opioid substitution therapy during pregnancy with either methadone (MMT) or buprenorphine (BUP) has been shown to reduce maternal illicit opioid use, improve prenatal care, and reduce maternal symptoms of craving and withdrawal [14–17]. Lifestyle improvements and reductions in illegal activity are also seen [18]. However, high rates of neonatal abstinence (40% to 80%) are still observed in both MMT and BUP exposed infants [14, 15, 19, 20]. Methadone is now the most commonly reported maternal medication associated with NAS (31%), followed by opioid pain relievers (24%) and buprenorphine (15%) [13]. Despite emerging evidence suggesting that buprenorphine substitution therapy may result in less severe and less prolonged NAS, in most centers, MMT remains the standard of care for treating opioid dependence during pregnancy [14, 21–23].

Infant adaptation to the postnatal environment is important for establishing optimal patterns of sleep, feeding, growth and in promoting parent-infant connection [24]. Early neurobehavioral studies using the Brazelton Neonatal Behavioral Assessment Scale (NBAS) showed that infants exposed prenatally to MMT were more state labile and exhibited more tremors, crying, hypertonicity, and behavioral dysregulation than unexposed infants [25]. More recent studies have compared the neurobehavior of methadone and buprenorphine exposed infants [21, 26–30] as well as those treated for NAS or not [31, 32]. These studies used the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) [33], which is a well-validated neurobehavioral measure designed specifically for the drug-exposed infant. Based on the NBAS, the NNNS assesses neurological and behavioral functioning and the extent of stress abstinence [33]. For example, a comparison of 21 MMT exposed and 16 BUP exposed infants found that MMT infants were more easily aroused, showed more signs of stress abstinence, and were more excitable [29].

Two further studies compared MMT exposed infants requiring pharmacotherapy for NAS and those who did not [31, 32]. One found that infants who received pharmacotherapy to treat their NAS were less able to habituate to visual and aural stimuli, were more easily aroused and excitable, and displayed more hypertonicity than untreated infants [31]. When the NNNS scores of both treated and untreated study infants were compared to normative data from an unexposed group [34], significant differences were found in scores of habituation, attention, handling, non-optimal reflexes, hypertonicity, hypotonicity and stress abstinence. In contrast, the second study found no neurobehavioral differences at 6 weeks postpartum between those receiving pharmacotherapy for NAS and those who did not [32]. However, both treated and untreated infants were characterized by more stress abstinence signs than unexposed comparison infants. Treated infants also had poorer self-regulation and quality of movements than comparison infants [32].

An enduring question concerning children exposed prenatally to MMT is whether there are ongoing effects on neurodevelopment. However, there is a lack of well-controlled

Competing interests: The authors have declared that no competing interests exist.
prospective longitudinal studies comparing the neurodevelopment of MMT exposed and unexposed infants. Of the 16 studies carried out prior to 1990 where comparative longitudinal data were reported, only five found significant, but small differences between MMT exposed and unexposed infants on the Mental Development Index (MDI) [35–39], and four found differences on the Psychomotor Development Index (PDI) [36, 38, 40, 41] of the Bayley Scales of Infant Development II [42]. Notable were the small samples in these studies and the low mean daily methadone dose (14–40 mg/day) prescribed to mothers at that time. The influence of other factors that might contribute to between group differences was also rarely adequately taken into account. More recently, the escalation in prescription opioid abuse and heroin has resulted in over 50 published reports on the neurodevelopment of children exposed prenatally to opioids, but few are prospective, well-controlled longitudinal studies of MMT (see review by Conradt et al. [43]). Of those prospective studies that compared children exposed prenatally to MMT with unexposed children, findings are equivocal with one study finding no differences in early cognitive or motor development [44], one study finding mild impairment in cognitive development [45], one lower scores on psychomotor outcomes at 6 months [46], and two other studies finding lower scores on cognitive outcomes at ages 4 [47], and 4.5 and 5.5 [48] years. However, most of these studies were limited by the inclusion of small numbers of participants or did not control for other drug use, which may explain the inconsistent findings.

A further explanation may be the varying infant susceptibility to the effects of prenatal exposure to MMT and other maternal and environmental factors that result in poorer neurodevelopmental outcomes for some groups of children. To date, most studies that have examined the effects of maternal MMT on the neurobehavior of the infant have used a variable-centered analysis, such as linear or multiple regression which examines the relationship between variables (e.g., to predict outcomes). These analyses assume participants have been sampled from a single population and do not take into account the unobserved heterogeneity that may exist within that population; they, therefore cannot explore how the heterogeneity in neurobehavioural profiles may differentially relate to MMT-related outcomes [49]. In comparison, person-centered analyses assume heterogeneity within the sampled population and that important subgroups of individuals can be identified by shared neurobehavioral attributes. Latent profile analyses, a person-centered approach, uses observed continuous data to assign class or group membership [50]. In this procedure, instead of focusing on a single component of neurobehaviour, latent profile analyses can use the full pattern of co-occurring neurobehavioral responses to categorize subgroups of infants. For instance, employing a person-centered analysis of the summary scores of the NNNS data, subgroups, or profiles of infants have been identified that are linked to poorer medical and behavioural outcomes. In a sample of infants exposed prenatally to cocaine, opiates, and other psychoactive drugs [51], distinct profiles of the NNNS summary scores obtained using latent profile analysis were associated with poorer clinical outcomes at birth and neurodevelopmental consequences that persisted over the first 4.5 years.

Given steep increases in NICU referrals of infants exposed prenatally to methadone and other opioids, the lack of well-controlled, longitudinal outcome studies, existing contradictory neurodevelopmental data, and recent findings showing evidence of neurobehavioral dysregulation among infants exposed to MMT, there is a clear need to better understand the early neurobehavior of these infants. Also important is the identification of those infants who may be more at risk for adverse neurodevelopmental outcomes at birth that extend beyond the perinatal period.

Using data from the prospective, longitudinal Christchurch Methadone In Pregnancy (MIP) Study, this report aims to investigate the following. First, to examine the neurobehavior
of MMT exposed infants at term equivalent relative to an unexposed group of infants on the NNNS. Second, to use a latent profile analysis of the summary scores on the NNNS to determine if there is a distinct profile of neurobehavior that characterizes infants with poorer clinical outcomes at birth and at 24 months.

Methods
Participants

The study sample included two groups of infants whose mothers were recruited during their second or third trimester of pregnancy in Christchurch, New Zealand, from 2003 to 2008.

**Methadone exposed group.** The first study group consisted of a consecutive series of 100 infants born to opioid-dependent women receiving daily methadone maintenance treatment (MMT) through the only regional service providing opioid substitution therapy. Inclusion criteria required mothers to be enrolled in MMT prior to their third trimester. Exclusion criteria included mother unable to give informed consent, poor spoken English, intention to deliver outside the region, very preterm birth (≤ 32 weeks gestation), fetal alcohol syndrome, infant congenital abnormalities or HIV positive. Over the recruitment period, 119 women were eligible for inclusion in the MMT group. Of these, 99 were recruited (83%), resulting in 100 live births (58 male, 42 female), including one set of twins. Reasons for sample loss included failure to recruit (n = 2) and refusal (n = 17). NNNS data for a further 8 infants were incomplete or missing, with an additional 6 infants needing to be excluded due to untestability on the NNNS defined as five unsuccessful assessment attempts.

Three quarters (76%) of mothers in the MMT group were receiving opioid substitution therapy when they became pregnant. Pregnancy doses ranged from 12.5 to 195.0 mg/day, with the highest mean methadone dose per trimester being 73.1±31.1mg/day in trimester 1, 67.8±31.8mg/day in trimester 2, and 68.9±34.3mg/day in trimester 3. A higher proportion of mothers increased their dose (33% 2nd semester and 21% 3rd semester) than decreased their dose (15% and 16%) over their pregnancy. The average maternal methadone dose across pregnancy was 61.8±35.3mg/day.

**Unexposed comparison group.** The second study group consisted of 110 infants born to women who were not enrolled in MMT. These infants were randomly selected from the maternity booking schedule for the Canterbury District Health Board, which serves both rural and urban areas within the Canterbury region. The same exclusion criteria were applied. A total of 169 untreated comparison women were identified. Of these, 108 women were recruited (65%), resulting in 110 live births (48 male, 62 female), including two sets of twins. Reasons for non-recruitment included inability to trace (N = 20) and refusal (N = 39). Control infants were born during the same time period and matched for expected birth date with children in the MMT group. Comparison of the socio-economic profile of women in this group with regional census data (Statistics NZ 2006) showed that this cohort was representative of the region from which they were recruited. Table 1 describes the maternal and infant characteristics of participants included in this report.

Procedure

Ethics approval was obtained from the Canterbury Regional Ethics Committee, and written informed consent obtained from all mothers. Near the end of the third trimester or directly after birth, mothers were interviewed about their socioeconomic status, education, and family circumstances as well as their obstetric, mental health and alcohol, tobacco, prescription and illicit drug use history (Table 1). This interview was conducted by a senior research nurse who was aware of the group status of the mothers but did not know the dose of methadone mothers
Table 1. Maternal background, obstetric history, and drug use during pregnancy and infant clinical characteristics at birth.

| Maternal Demographics & Background | Exposed MMT N = 86 | Comparison N = 103 | P value |
|-----------------------------------|------------------|-------------------|--------|
| Maternal age (yr)                 | 30.07 (6.11)     | 31.07 (6.61)     | .289   |
| NZ Maori                           | 16 (19%)         | 12 (12%)         | .178   |
| NZ European                        | 71 (83%)         | 88 (85%)         | .292   |
| Pacific Islands, Asian & other     | 2 (2%)           | 8 (8%)           | .097   |
| Single parent family               | 34 (40%)         | 18 (18%)         | .001   |
| No maternal educational qualification | 56 (65%)     | 34 (33%)         | < .001 |
| Social welfare dependent           | 79 (93%)         | 18 (18%)         | < .001 |
| Maternal Factors                   |                  |                  |        |
| Primigravida                        | 6 (7%)           | 39 (38%)         | < .001 |
| History of termination             | 36 (42%)         | 12 (12%)         | < .001 |
| Previous live births               | 2 (0–7)          | 1 (0–7)          | < .001 |
| Any maternal or hospital report of mental illness | 55 (64%) | 14 (14%) | < .001 |
| Maternal Pregnancy Drug Use        |                  |                  |        |
| Alcohol use in pregnancy           | 14 (16%)         | 22 (21%)         | .376   |
| Average drinks per week            | 0.75 (2.71)      | 0.33 (1.04)      | .146   |
| Median (range)                     | 0 (0–20)         | 0 (0–8)          |        |
| Smoked cigarettes in pregnancy     | 80 (93%)         | 17 (17%)         | < .001 |
| Average cigarettes per day         | 13.64 (9.27)     | 1.42 (3.92)      | < .001 |
| Median (range)                     | 11 (0–40)        | 0 (0–15)         |        |
| Marijuana                           | 45 (52%)         | 2 (2%)           | < .001 |
| Average joints per week            | 1.28 (2.20)      | 0.03 (0.10)      | < .001 |
| Median (range)                     | 0.33 (0–10)      | 0.0 (0–1)        |        |
| Benzodiazepines                    | 23 (27%)         | 2 (0%)           | < .001 |
| Average times used per week        | 0.71 (1.99)      | 0                | < .001 |
| Median (range)                     | 0 (0–14)         | 0                |        |
| Stimulants                          | 16 (19%)         | 1 (1%)           | < .001 |
| Average times used per week        | 0.58 (1.62)      | 0.03 (0.26)      | < .001 |
| Median (range)                     | 0 (0–9)          | 0 (0–3)          |        |
| Illicit opiates                    | 22 (26%)         | 0 (0%)           | < .001 |
| Average times used per week        | 1.27 (2.99)      | 0                | < .001 |
| Median (range)                     | 0 (0–19)         | 0                |        |
| Prescribed medications             | 24 (28%)         | 17 (17%)         | .058   |
| Ritalin                            | 5 (5.8%)         | 0                | .018   |
| SSRIs                              | 2 (2.3%)         | 5 (4.9%)         | .458   |
| Benzodiazepines                    | 4 (4.7%)         | 1 (1.0%)         | .179   |
| Used > 2 prescribed, legal or illegal drugs | 35 (41%) | 2 (2%) | < .001 |
| Infant Birth Outcomes              |                  |                  |        |
| Male                               | 49 (57%)         | 47 (46%)         | .120   |
| Apgar 1                            | 8.21 (1.72)      | 8.32 (1.55)      | .657   |
| Apgar 5                            | 9.63 (0.66)      | 9.52 (0.93)      | .375   |
| Born preterm < 37 weeks            | 11 (13%)         | 7 (7%)           | .162   |
| Gestational age (weeks)            | 38.76 (1.80)     | 39.25 (1.69)     | .054   |
| Birth weight (gm)                  | 3049.73 (459.74) | 3428.03 (587.15) | < .001 |
| Birth head circumference (cms)     | 33.88 (1.51)     | 34.73 (1.44)     | < .001 |
| Birth length (cm)                  | 50.17 (3.10)     | 52.18 (3.15)     | < .001 |
| Referred to NICU                   | 13 (16%)         | 2 (2%)           | .001   |

(Continued)
in the MMT group were prescribed or the length of time they had been receiving MMT. Maternal and infant chart reviews provided further information about maternal obstetric history, mental health status, prescribed medications that included antidepressants, antipsychotics, and anti-epileptics, and infant clinical outcomes. A detailed description of the psychosocial characteristics and patterns of poly-drug use of women enrolled in the MIP study is published elsewhere [52].

**Measures**

**Maternal licit and illicit drug use.** Detailed information about maternal use of licit and illicit psychoactive drugs and dependence during pregnancy was obtained from the Composite International Diagnostic Interview (CIDI) [53]. For each substance (tobacco, alcohol, cannabis, opiates, benzodiazepines, and stimulants), women were asked about the frequency and extent of their use before pregnancy and during each trimester. For the purposes of these analyses we used the average number of cigarettes per day, the average number of drinks consumed and joints smoked per week, and the average number of times stimulants, other opiates and benzodiazepines were used per week across pregnancy. Finally, maternal licit and illicit psychoactive drug use was further independently assessed via random maternal urine samples during pregnancy of 49 (61%) of MMT women (2.8 samples/woman). This information was cross-checked against maternal self-reported drug use to create overall measures of maternal pregnancy licit and illicit drug use. Discrepant positive urine results were found for only 5 of the 49 women who had not reported use of a specific substance. For analysis, women who reported use of a licit or illicit psychoactive drug or who had a positive urine test result of one were considered to have used that drug during the trimester in which the test was carried out.

**NICU Network Neurobehavioral Scale (NNNS).** All study infants had an NNNS assessment within one week of birth or corrected gestational age for infants born preterm (32–37 weeks) after they were deemed stable by the medical team. The median and range of ages at assessment for each group were: MIPS median age = 42.00, range 37.00 to 49.00 vs Comparison median age = 42.00, 39.00 to 46.00. For most infants, this was done prior to hospital discharge at a time when they were midway between feeds, and the infant was asleep. For a small proportion of infants discharged early from the hospital (N = 12, 6%), to minimize sample loss, the NNNS was done at home in a quiet room under the same conditions. The NNNS is a standardized neurological exam which measures a newborn infant’s neurological function, behavior and signs of stress abstinence [33, 54]. “Packages” of neurologic behavior are administered in a set order to produce 13 summary scores based on structured observations of active and passive tone, primitive reflexes, state transitions, and orientation to animate and inanimate visual and aural stimuli and signs of stress/abstinence (Table 2). Higher scores on the

---

**Table 1. (Continued)**

|                          | Exposed MMT N = 86 | Comparison N = 103 | *P* value |
|--------------------------|--------------------|--------------------|-----------|
| Days in Special Care Baby Unit | 11 (0–55)          | 0 (0–14)           | < .001    |
| Total days in hospital   | 12 (0–55)          | 3 (0–14)           | < .001    |
| Corrected gestational age NNNS completed | 41.93 (2.19) | 41.83 (1.44) | .713     |
| Treated for NAS          | 73 (88%)           | -                  | -         |
| Treated with morphine only | 55 (64%)          | -                  | -         |
| Treated with morphine & phenobarbital | 18 (22%)          | -                  | -         |

Data are Mean (SD), Median (range) or N (%). Maternal drug use is reported in N (%), average cigarettes per day, drinks per week, joints per week, and average number of times other opiates, stimulants, and benzodiazepines used per week across pregnancy, median, and range.

https://doi.org/10.1371/journal.pone.0240905.t001
attention, regulation, and quality of movement scales are more optimal. Whereas, lower scores on habituation, arousal, handling, excitability, lethargy, non-optimal and asymmetric reflexes, hypertonicity, and hypotonicity indicate better function. Stress/abstinence is scored as “yes” or “no” from a list of signs of withdrawal organized by organ system (50 items). The NNNS was administered by one of three examiners trained to reliability and blind to group status.

### Neurodevelopment at age 24 months.

The Bayley Scales of Infant Development Version 2 (BSID-II) [55] was administered by a blinded clinical psychologist at age 2 years (corrected for prematurity) as part of a larger neurodevelopmental follow-up. The BSID-II is a standardized measure of child cognitive (Mental Developmental Index or MDI) and neuromotor function (Psychomotor Developmental Index or PDI).

### Statistical analysis

**Exploratory data analysis.** All analyses were conducted with SPSS version 26. All infant birth data were complete, with 96% of the infants available for follow-up at 24 months on the Bayley MDI and PDI. Outliers were identified by visually examining box plots of the methadone and comparison groups separately and combined. Outliers in the NNNS Summary scores were identified in both the MMT and comparison groups and were in the same direction (either higher or lower scores) for Non-optimal reflexes, Attention, Handling, Stress Abstinence, Quality of Movement, Asymmetrical Reflexes. Outliers were also found for both groups in the summary scores of physiological, autonomic, visual, and Genitourinary (GI) stress. Analyses were run with and without outliers, and no substantial differences were found for any of the above summary scores. Assumptions of normality, linearity, and homogeneity of variance were confirmed with visual examination of the frequency distributions, histograms, and residual scatter plots. Skewness and kurtosis for all but four of the variables above were all around +/- 1.00. In addition, when the means and medians of these variables were compared, they were similar. Further visual examination of frequency distributions and histograms of Hypertonicity, Hypotonicity, Asymmetrical Reflexes and Excitability all showed distributions skewed towards more

### Table 2. Summary scores (excluding habituation) of the NICU Network Neurobehavioral Scale (NNNS).

| Scale                  | Description                                                                                                                                                                                                 |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Attention              | High scores indicate an infant’s sustained ability to attend and respond appropriately to auditory and visual stimulation.                                                                                     |
| Handling               | High scores suggest that the infant required substantial soothing and settling by the examiner to maintain a quiet alert state to elicit attention and to respond to auditory and visual stimuli.               |
| Self-regulation        | High scores suggest the infant has a better ability to self-regulate and cope with the demands of the NNNS examination.                                                                                       |
| Arousal                | High scores suggest the infant exhibited higher levels of fussing, crying and associated motor activity throughout the examination.                                                                            |
| Excitability           | High scores indicate an infant exhibited high levels of motor, state, and physiological reactivity and irritability even with repeated attempts at soothing by the examiner.                                        |
| Lethargy               | High scores suggest the infant was continually under aroused.                                                                                                                                                |
| Hypertonicity          | High scores indicate the infant exhibited tight muscle tone in the arms, legs, and trunk.                                                                                                                    |
| Hypotonicity           | High scores indicate the infant had consistently low muscle tone in the arms, legs and trunk.                                                                                                               |
| Non-optimal Reflexes   | The number of Non-optimal reflex responses on upper and lower extremities. (Higher scores less optimal).                                                                                            |
| Asymetric Reflexes     | The number of times a reflex on one side of the body is stronger/weaker than the other. (Higher scores less optimal)                                                                                         |
| Quality of Movement    | High scores suggest more mature motor control, including: smoothness and modulation of movement of the arms and legs, as well as tremors and startles.                                                         |
| Stress Abstinence      | The number of stress abstinence signs an infant exhibited across seven categories: Autonomic, physiological, CNS, visual, gastrointestinal, skin, state. (High scores less optimal)     |

https://doi.org/10.1371/journal.pone.0240905.t002
optimal summary scores (low scores) for all four scales for both groups, the subcategories of abstinence were also significantly skewed towards lower values.

Analyses were run with and without the 3 sets of twins included in our sample (1 set in the MMT group and 2 in the comparison group). As there were no differences when these were included or excluded in all analyses, results are reported for the whole sample.

**Between group differences.** T-tests, Kruskall-Wallis, and Chi-square statistics were used to examine social background, maternal licit and illicit psychoactive and prescribed drugs and other infant clinical differences at birth between MMT exposed and comparison groups at birth (Table 1). Robust empirical variance structures were used in generalized linear models (GLIM) to overcome slight deviations from normality and for those summary scores that were significantly skewed. Differences between the MMT exposed and comparison infants on individual summary scores of the NNNS and neurodevelopmental outcomes at age 24 months were tested using GLIM with a link function. For those summary scores that were significantly skewed towards lower scores, gamma models with a log function were employed. GLIM were also used to compare the daily dose of methadone mothers were receiving during pregnancy and summary scores on the NNNS. MMT dose was categorized as no, low (≤64 mg) or high dose (>65 mg) averaged across pregnancy, and similarly categorized for the highest individual recorded dose during the third trimester. High, low and no dose were dummy coded as 2, 1 and 0, respectively. High dose was selected as the reference category in GLIM models. GLIM analyses were conducted with and without covariates, as described below.

**Adjustment for covariates.** A range of covariates were selected based on previous research and theory linking these factors to pregnancy drug use and infant neurobehavioral outcomes (see Table 1). These were further checked for multicollinearity and composite measures created if necessary. GLIM models were then fitted using forwards and backwards variable elimination to identify the best fitting and most parsimonious models. Covariates were retained in the model if they changed the effect estimates of the unadjusted relation between NNNS summary scores and MMT exposure by more than 5%. All analyses were adjusted for the corrected age of NNNS assessment, socioeconomic status as well as the following covariates: 1) maternal prescription drug and psychoactive licit and illicit drug use during pregnancy including medications prescribed across pregnancy (SSRIs, benzodiazepines & ritalin), average number of cigarettes per day, average number of drinks and average number of joints of marijuana per week, average times benzodiazepines, other opiates or stimulants were used per week across pregnancy; 2) infant characteristics including birth weight, sex and gestational age in completed weeks; 3) maternal obstetric and mental health history including number of terminations, gravida and documented or self-reported history of mental illness.

**Latent profile analysis.** Latent profile analysis (LPA) was used to classify individual infants into homogeneous subgroups or latent profiles. Data suitable for LPA usually consists of unobservable subgroups of individuals with different probability distributions. LPA is an extension of Latent Class Analysis, a model-based clustering technique [56]. The advantage of LPA over LCA is that it can accommodate continuous, ordinal, and binary indicators. Profiles of infants in this study were determined using the 12 NNNS summary scores. Habituation summary scores were excluded since only 51% of the MMT exposed, and 37% of comparison infants completed this package. Hypertonicity and hypotonicity summary scores were dichotomized (yes/no), with all other scores treated as continuous variables. Infants who shared similar patterns across these scores were allocated to discrete profiles with the goal of minimizing the heterogeneity of the NNNS summary scores in one profile and maximizing the heterogeneity of scores across other profiles. Latent profile analyses were conducted with the Mplus 7 statistical package using finite mixture modeling [57]. Random starts were used to ensure replication of the best log-likelihood and to avoid local maxima.
The final number of profiles was determined by exploring a varying number and selecting the profiles that made the most sense in relation to theory, and previous research [51, 58], the nature of the groups, and interpretation of the results—as well as alternate goodness-of-fit indices and tests of statistical significance (Table 3). Two profiles were initially specified and were increased by one in subsequent analyses until the final model was obtained. At each step, changes in the Bayesian Information Criterion (BIC) adjusted for sample size was used to assess model fit. The number of profiles was determined to be appropriate at the point where no significant drop in BIC was observed as the profile number increased. Model fit and optimum number of profiles were also assessed with the bootstrap log likelihood ratio (LR) difference test [59], and the average posterior probability (entropy).

When the final number of profiles were obtained, standardized scores were computed to compare summary scores on the same scale across the different profiles. Each summary score was subtracted from the overall mean of individual scores and divided by the overall standard deviation for that summary score. Differences in mean summary profiles on maternal and infant characteristics at birth, and neurodevelopmental outcomes at 24 months were examined using t-tests or Kruskall-Wallis for continuous variables and Chi-square for dichotomous variables.

Results

Neurobehavioral outcomes of infants exposed to methadone during pregnancy

There was no difference in the mean infant gestational age at the time of NNNS assessment between infants prenatally exposed to MMT and unexposed infants (MMT exposed M = 41.5 ±5.3 weeks vs unexposed M = 41.7±1.5 weeks). However, infants in the MMT group were significantly more likely to require more than 2 attempts to complete the NNNS than comparison group infants (11% v. 2%, \( p = .025 \)). Twelve infants were administered the NNNS in the home after discharge from hospital (Mean gestational age at hospital = 39.2, SD = 1.41 vs home = 38.7, SD = 1.85, \( p = .392 \)). Of those 12, only one was from the comparison group. Of the remaining 11 infants from the methadone group, \( N = 11 \) (100%) were infants who received pharmacotherapy treatment for NAS. Although there were no systematic differences across summary scores, there were three summary scale scores where there were significant differences. More Stress Abstinence (M = .15, SD = .11, vs M = .21, SD = .11, \( p = .024 \)) and Arousal (M = 4.09, SD = .75 vs M = 4.68, SD = .65, \( p < .017 \)) were observed among infants administered at home, and scores on Quality of Movement that were more optimal (M = 4.30, SD = .87 vs M = 3.23, SD = .71, \( p = < .001 \)).

Table 3. Model fit and model comparisons for 2, 3 or 4 profiles.

| Latent Profiles | Sample-Size Adjusted Bayesian Information Criterion (BIC) \( ^{b} \) | Entropy \( ^{b} \) | Bootstrapped Log Likelihood Ratio Test for 1 Less Class or Profile \( ^{c} \) |
|-----------------|-----------------------------|-----------------|---------------------------------|
| 2               | 4546.199                    | .932            | -2484.238 \( ^{a} \)           |
| 3               | 4457.749                    | .914            | -2236.801 \( ^{a} \)           |
| 4               | 4327.245                    | .911            | -2153.002 \( ^{a} \)           |

\( ^{a} \)p < .0001. \\
\( ^{b} \)Model fit lower values are better. \\
\( ^{c} \)Measure of how clearly distinguishable the classes are based on individual’s estimated class probability. This should be close to 1.0. \\
\( ^{a} \)Compares model with G profiles or classes with G– 1 (3 vs 4 profiles). A significant Ratio indicates the model with 1 more profile has a better relative fit than the model with 1 less profile (4 profiles better than 3).
Table 4 describes the neurobehavior of infants born to mothers maintained on methadone during pregnancy and unexposed comparison infants based on the GLIM analyses. Results given include the unadjusted and adjusted means, the unstandardized regression coefficients (B), and the Wald 95% confidence intervals (CI) adjusted for the covariates for the 12 NNNS summary scores and the seven subcategories of abstinence.

Relative to the comparison group, MMT exposed infants had a number of summary scores on the NNNS that suggest poorer neurobehaviour in a number of domains. After adjustment for covariates MMT exposed infants had poorer attention (M = 5.83, SD = 1.54 vs M = 6.78, SD = 1.42, p < .001), regulation (M = 5.38, SD = 0.88 vs M = 6.23, SD = 0.79, p = < .001), and quality of movement (M = 4.15, SD = 0.92 vs M = 4.87, SD = 0.71, p = < .001). They were also significantly more excitable (M = 3.67, SD = 1.95 vs M = 1.85, SD = 1.42, p = < .001), more easily aroused (M = 4.17, SD = 0.66 vs M = 3.77, SD = 0.81, p = < .001), exhibited more non-optimal reflexes (M = 4.02, SD = 1.95 vs M = 3.15, SD = 1.93, p = .003), and more hypertonicity (M = 0.49, SD = 0.58 vs M = 0.10, SD = 0.53, p = < .001). Finally, MMT exposed infants exhibited more total stress abstinence signs (M = 0.15, SD = 0.07 vs M = 0.09, SD = 0.07, p = < .001) and higher scores than comparison infants on CNS (M = 0.21, SD = 0.11 vs M = 0.21–0.11, SD = 0.15, p = < .001), visual (M = 0.11, SD = 0.09 vs M = 0.07, SD = 0.07, SD = 0.08, p = .002), genitourinary (GI) (M = 0.05, 0.10, SD = 0.10 vs M = 0.05, SD = 0.10, p = .051) and state (M = 5.61, SD = 1.01 vs M = 5.24, SD = 1.01, p < .001) indices of abstinence.

The effect of maternal methadone dose across pregnancy on infant neurobehavioral scores was examined using GLIM before and after adjustment for the effects of covariates. Of interest was whether high maternal methadone dose (≥65mg) was associated with greater neurobehavioral decrements in comparison to infants born to low (<64mg) methadone dose and no

Table 4. NNNS summary scores by exposure to methadone maintenance treatment unadjusted and adjusted for covariates.

| NNNS Summary Scores Mean (SD) | Unadjusted | Adjusted | Unadj | Adj | B | Sig |
|-------------------------------|------------|----------|-------|-----|---|-----|
| N | Methadone | N | Comparison | Methadone | Comparison | P | P | (Wald 95% C-I) | Cov |
|----|-----------|----|------------|-----------|-------------|---|---|----------------|-----|
| Attention | 71 | 5.83 (1.54) | 98 | 6.78 (1.23) | 5.83 (1.54) | 6.78 (1.42) | < .001 | < .001 | -0.95 (-1.38 - -0.52) | |
| Arousal | 85 | 4.17 (0.79) | 103 | 3.78 (0.56) | 4.17 (0.66) | 3.77 (0.81) | < .001 | < .001 | 0.40 (0.21–0.60) | 4 |
| Regulation | 85 | 5.39 (0.97) | 103 | 6.22 (0.80) | 5.38 (0.88) | 6.23 (0.79) | < .001 | < .001 | -0.86 (-1.16 - -0.59) | 2,5 |
| Handling | 84 | 0.30 (0.37) | 103 | 0.18 (0.36) | 0.28 (0.37) | 0.42 (0.31) | .009 | .094 | 0.07 (-0.1 - .14) | 4 |
| Quality of Movement | 84 | 4.16 (0.92) | 103 | 4.87 (0.71) | 4.15 (0.92) | 4.87 (0.71) | < .001 | < .001 | -0.16 (-0.22–0.11) | 4 |
| Excitability | 86 | 3.60 (2.69) | 103 | 1.90 (1.93) | 3.67 (1.95) | 1.85 (1.42) | < .001 | < .001 | 0.50 (0.32–0.67) | 2 |
| Lethargy | 86 | 3.29 (2.37) | 103 | 3.06 (1.43) | 3.29 (2.37) | 3.06 (1.43) | .424 | .424 | 0.23 (-0.34–0.80) | |
| Non-Optimal Reflex | 86 | 4.02 (1.95) | 103 | 3.15 (1.93) | 4.02 (1.95) | 3.15 (1.93) | .003 | .003 | 0.88 (0.30–1.46) | |
| Asymmetrical Reflex | 86 | 0.72 (1.06) | 103 | 0.56 (0.78) | 0.72 (1.06) | 0.56 (0.78) | .241 | .241 | 0.10 (-0.06–0.26) | |
| Hypertonicity | 86 | 0.51 (0.65) | 103 | 0.08 (0.31) | 0.49 (0.58) | 0.10 (0.53) | < .001 | < .001 | 0.34 (0.21–0.44) | 1 |
| Hypotonicity | 86 | 0.15 (0.37) | 103 | 0.17 (0.41) | 0.15 (0.37) | 0.17 (0.41) | .692 | .692 | 0.02 (0.05 - .12) | |
| Stress Abstinence | 86 | 0.16 (0.07) | 103 | 0.09 (0.07) | 0.15 (0.07) | 0.09 (0.07) | < .001 | < .001 | 0.05 (0.03–0.07) | 1,2,3 |
| Physiological | 86 | 0.10 (0.21) | 103 | 0.05 (0.20) | 0.10 (0.21) | 0.05 (0.20) | .149 | .149 | 0.04 (-0.02-0.10) | |
| Autonomic | 86 | 0.24 (0.20) | 103 | 0.19 (0.18) | 0.24 (0.20) | 0.19 (0.18) | .091 | - | 0.04 (-0.01–0.08) | |
| CNS | 86 | 0.21 (0.18) | 103 | 0.12 (0.20) | 0.21 (0.15) | 0.11 (0.15) | < .001 | < .001 | 0.08 (0.04–0.12) | 4 |
| Skin | 86 | 0.11 (0.10) | 103 | 0.08 (0.10) | 0.11 (0.10) | .061 | - | 0.03 (0–0.06) | |
| Visual | 82 | 0.11 (0.09) | 103 | 0.07 (0.08) | 0.11 (0.09) | 0.07 (0.08) | .002 | .002 | 0.04 (0.01–0.06) | |
| GI | 86 | 0.05 (0.10) | 103 | 0.02 (0.10) | 0.05 (0.10) | 0.02 (0.10) | .051 | .051 | 0.03 (0–0.06) | |
| State | 86 | 5.61 (1.04) | 103 | 5.24 (1.01) | 5.61 (1.04) | 5.24 (1.04) | < .001 | < .001 | 0.13 (0.09–0.16) | |

Significant covariates in the models of NNNS summary scores: 1 = Ritalin, 2 = Benzodiazepines, 3 = Infant birth weight, 4 = Corrected gestational age NNNS completed, 5 = gestational age at birth (completed weeks).

https://doi.org/10.1371/journal.pone.0240905.t004
dose (control) mothers. Compared to the low and no dose groups (M = 0.38, SD = 0.58, M = 0.07, SD = 0.06, respectively) the high dose group had higher scores on hypertonicity (M = 0.64, SD = 0.09, B = -0.56, CI -0.35 - -0.76) after adjusting for covariates. No effects of dose were associated with any other NNNS summary scores.

**NNNS profiles**

The optimal number of profiles were determined by fitting two to five profiles. The decrease in the BIC value adjusted for sample size with each increase in profile suggested improved goodness of fit (see Table 2). The five-profile model had the smallest BIC, but the fifth group contained only 5 infants suggesting that a four-profile model was the best fit for the data. Model fit and the optimum number of profiles were further evaluated with the bootstrap log likelihood ratio (LR) difference test [59], and the average posterior probability (entropy). Both tests supported a four-profile model. To determine whether the four-profile solution specified four unique classes, NNNS summary scores were compared across profiles and found to be significant for all scales (Table 5).

Standardized summary scores were plotted to demonstrate the pattern of each profile (Fig 1). Profile 1 included 31 (18%) infants. This profile was distinguished by the lowest attention and arousal and the highest lethargy scores, but with scores close to average on handling, self-regulation, asymmetric reflexes, quality of movement, and stress abstinence (Table 5). The 84 (44%) infants in profile 2 showed the most optimal neurobehavioral pattern requiring the least amount of handling, with better attention and self-regulation, and lower levels of arousability than profiles 3 and 4. They also demonstrated average levels of lethargy, the lowest scores on hypertonicity, hypotonicity, non-optimal reflexes and stress abstinence, and the highest quality of movements score. The 50 (27%) infants in profile 3 scored near the average on all measures, but had higher scores on excitability and arousal than profiles 1 and 2. Profile 4 infants showed the poorest profile of neurobehaviour. These 24 (13%) infants had poorer attention scores than profiles 2 and 3, required the most handling, had the lowest scores on self-regulation, and the highest on arousal, excitability, hypertonicity, non-optimal and asymmetric reflexes, and exhibited the highest stress abstinence and the poorest quality of movement.

**Validation and prediction of NNNS profiles.** To evaluate the profile classifications, profiles 1, 2 and 3 were compared to profile 4 across a range of maternal and infant characteristics

| NNNS Summary Score | Profile 1 N = 31 | Profile 2 N = 84 | Profile 3 N = 50 | Profile 4 N = 24 | P value |
|---------------------|-----------------|-----------------|-----------------|-----------------|---------|
| Attention           | 4.53 (1.04)     | 7.22 (0.78)     | 6.46 (1.12)     | 5.14 (1.66)     | <.001   |
| Handling            | 0.21 (0.27)     | 0.11 (0.20)     | 0.33 (0.33)     | 0.46 (0.38)     | <.001   |
| Self Regulation     | 5.52 (0.55)     | 6.61 (0.61)     | 5.45 (0.56)     | 4.42 (0.73)     | <.001   |
| Arousal             | 3.39 (0.46)     | 3.58 (0.34)     | 4.41 (0.44)     | 5.00 (0.44)     | <.001   |
| Excitability        | 0.39 (0.80)     | 0.31 (0.56)     | 1.84 (1.42)     | 3.79 (1.50)     | <.001   |
| Lethargy            | 5.71 (1.35)     | 2.95 (1.19)     | 2.20 (1.26)     | 2.63 (2.81)     | <.001   |
| Hypertonicity       | 13 (42%)        | 3 (4%)          | 8 (16%)         | 13 (54%)        | <.001   |
| Hypotoncity         | 9 (29%)         | 7 (8%)          | 8 (16%)         | 4 (17%)         | .049    |
| Non-optimal Reflexes| 4.29 (1.64)     | 2.95 (1.73)     | 3.42 (1.85)     | 4.92 (2.83)     | <.001   |
| Asymmetric Reflexes | 0.58 (0.76)     | 0.44 (0.66)     | 0.66 (0.77)     | 1.33 (1.61)     | <.001   |
| Quality of Movement | 4.51 (0.75)     | 4.98 (0.63)     | 4.50 (0.73)     | 3.20 (0.78)     | <.001   |
| Stress Abstinence   | 0.58 (0.76)     | 0.44 (0.66)     | 0.66 (0.77)     | 1.33 (1.60)     | <.001   |

Mean (SD) and Number (%).
Infants in profile 4 were significantly more likely to be born to a mother on government welfare (83% vs 47%, \( p = .001 \)), and with a history of significantly more pregnancies and terminations than those in the other 3 profiles. Profile 4 infants had significantly more prenatal exposure to legal and illegal psychoactive drugs. Mothers of these infants were receiving MMT in all 3 trimesters and used tobacco and stimulants during pregnancy.

Given that infants in profile 4 showed the poorest performance on the NNNS, we hypothesized that this group would have poorer clinical outcomes at birth and poorer neurodevelopment at age 2 years. As shown in Table 6, a significantly higher percentage of infants in profile 4 were male (71% vs 48%, \( p = .036 \)), born preterm (21% vs 8%, \( p = .043 \)), and were significantly smaller at birth. A higher proportion of profile 4 infants spent more than 2 weeks in a special care baby unit (42% vs 14%, \( p = .001 \)) and more than 2 weeks in hospital postnatally (33% vs 12%, \( p = .005 \)). Finally, a higher percentage of these infants required pharmacological (morphine) treatment for NAS (83% vs 33%, \( p = < .001 \)) typically for longer than a month (78% vs 27%, \( p = < .001 \)). At 24 months, profile 4 infants had significantly lower mean scores than the other three profiles on the BSID-II, MDI (M = 78.96, SD = 18.61 vs 87.94, SD = 18.00, \( p = .025 \), partial \( \eta^2 = .03 \)) and PDI (M = 80.92, SD = 24.05 vs M = 92.03, SD = 17.81, \( p = .007 \), partial \( \eta^2 = .04 \)).
Table 6. Comparison of profile 4 vs profiles 1–3.

| Demographics                          | Profile 4 N = 24 | Profiles 1–3 N = 165 | P value |
|---------------------------------------|------------------|----------------------|---------|
| Maternal age (yr)                     | 30.13 (4.70)     | 30.68 (6.64)         | .691    |
| Maori                                 | 5 (21%)          | 23 (14%)             | .389    |
| NZ European                           | 17 (71%)         | 124 (76%)            | .578    |
| Other European                        | 3 (13%)          | 14 (9%)              | .534    |
| Pacific islands, Asian & Other        | 1 (4%)           | 9 (6%)               | .783    |
| Single or no partner at birth          | 8 (33%)          | 44 (27%)             | .494    |
| No educational qualification          | 14 (58%)         | 76 (46%)             | .261    |
| Receiving government benefit          | 20 (83%)         | 77 (47%)             | .001    |

| Prenatal Legal or Illegal Psychoactive Drug Exposure | |
|------------------------------------------------------|---------|
| Receiving MMT                                        | 21 (88%)| 76 (46%) | <.001   |
| Receiving MMT all 3 trimesters                       | 20 (83%)| 66 (41%)| <.001   |
| Alcohol                                              | 4 (17%) | 32 (19%)| .751    |
| Tobacco                                              | 21 (88%)| 76 (46%)| <.001   |
| Marijuana                                            | 8 (33%) | 76 (46%)| .304    |
| Opiates other than MMT                               | 5 (21%) | 17 (10%)| .133    |
| Stimulants                                           | 7 (29%) | 10 (6%) | <.001   |
| Benzodiazepines                                      | 4 (17%) | 19 (12%)| .471    |
| Prescribed medication                                | 8 (33%) | 33 (20%)| .139    |
| Used more than 2 psychoactive drugs in pregnancy     | 9 (38%) | 28 (17%)| .018    |

| Maternal Obstetric History                        | |
|---------------------------------------------------|---------|
| Primigravida                                       | 3 (13%) | 42 (26%)| .164    |
| History of Termination                             | 11 (46%)| 37 (22%)| .014    |
| History of still born or miscarriage               | 11 (46%)| 51 (31%)| .146    |
| Number of live births                              | 1.42 (1.21)| 1.36 (1.50)| .854    |
| Number of previous pregnancies                     | 3.63 (3.16)| 2.33 (2.48)| .023    |
| Any maternal mental illness                        | 11 (46%)| 58 (35%)| .310    |

| Infant Clinical Outcomes                          | |
|---------------------------------------------------|---------|
| Male                                               | 17 (71%)| 79 (48%)| .036    |
| Gestational age (wk)                               | 38.07 (2.06)| 39.16 (1.67)| .004    |
| Born Preterm (< 37 wk)                             | 5 (21%) | 13 (8%) | .043    |
| Birth weight (gm)                                  | 2973.33 (412.45)| 3297 (572.40)| .008    |
| Birth head circumference (cm)                      | 33.65 (1.65)| 34.44 (1.50)| .017    |
| Birth length (cm)                                  | 49.67 (3.12)| 51.49 (3.23)| .010    |
| > 2 weeks in special care nursery                  | 10 (42%)| 22 (14%)| .001    |
| > 2 weeks total stay in hospital                   | 8 (33%) | 19 (12%)| .005    |
| NAS treated with morphine                          | 19 (83%)| 54 (33%)| <.001   |
| > 1 month morphine treatment                       | 18 (78%)| 42 (27%)| <.001   |
| NAS treated with phenobarbital                     | 5 (22%) | 13 (18%)| .038    |
| > 1 month phenobarbital treatment                  | 5 (23%) | 9 (6%)  | .005    |

| Development at 24 Months                          | |
|---------------------------------------------------|---------|
| BAYLEY-II MDI                                      | 78.96 (18.61)| 87.94 (18.00)| .025    |
| BAYLEY-II PDI                                      | 80.92 (24.05)| 92.03 (17.81)| .007    |

N (%), or Mean (SD).
Discussion

This prospective, longitudinal study compared the neurobehavior of infants born to mothers receiving MMT for opioid dependence with a group of non-methadone exposed infants born to mothers who were randomly selected from the general obstetric population at the largest maternity hospital in the region. Using the summary scores from the NNNS and a clustering technique using all data, we characterized four distinct profiles of infant neurobehavior. These profiles were associated with differing clinical outcomes at birth and neurodevelopment at age 24 months.

The main outcome of this study was the identification of unique effects of MMT on newborn neurobehavior. After controlling for covariates, including other psychoactive drug use and socioeconomic status, MMT exposed infants had poorer attention, were more easily aroused, more excitable, and had poorer behavioral regulation than unexposed infants. They also exhibited poorer quality of movement, non-optimal reflexes, and more hypertonicity. Finally, they exhibited more signs of stress abstinence that spanned disturbances to state regulation and the CNS, visual and genitourinary systems. An examination of the dose effects on these patterns of behavior found that increased hypertonicity alone was associated with exposure to higher maternal methadone doses (>65 mg per day).

Of the four discrete neurobehavioral profiles identified, the poorest neurobehavioral functioning was observed in the small subsample of 24 (13%) infants in profile 4. These infants exhibited the most stress abstinence, poorest state regulation, and ability to maintain an alert attentive state; were more easily aroused and excitable; required more handling/soothing, were more hypertonic and showed more non-optimal and asymmetric reflexes. This group was over-represented by MMT exposed infants (88%) and a higher proportion were exposed prenatally to tobacco (88%) and stimulants (29%). Their mothers had more pregnancies and terminations and were almost twice as likely to have been in MMT throughout their pregnancy relative to Profile 1–3 infants. Profile 4 infants also exhibited more worrisome clinical outcomes at birth, including being more likely to be born preterm (21%) and symmetrically smaller than infants in profiles 1–3. In addition, a higher proportion (78%) required extended (>1 month) NAS treatment (83%) and spent longer in hospital (33%). At the corrected age of 24 months, these infants were more likely to be lagging behind their peers neurodevelopmentally, obtaining mean cognitive and psychomotor scores that were 1.5 and >1 standard deviation below the norms, respectively. In contrast, group 2 had the most optimal neurobehavioral profile and tended to be over-representative of control and/or lower dose MMT mothers (Table 5).

The finding that MMT exposed infants have a more dysregulated pattern of neurobehavior at birth than unexposed infants is consistent with the work of Velez et al. [31] and to some extent Heller et al. [32] as reviewed earlier. However, in contrast to Heller et al. [32] who found that adverse neurobehavioral findings were confined primarily to NAS treated infants, we found MMT exposed infants exhibited more dysregulated neurobehavior, regardless of whether they required treatment for NAS or not. The possible absence of further associations between MMT and poorer neurobehavioral outcomes by Heller et al. [32] may reflect limited statistical power due to their small sample size. It may also, as the authors suggest, reflect maturation or developmental changes in the CNS over the first month. Coyle et al. [29] found changes over the first month postnatally in NNNS summary scores in both MMT exposed and buprenorphine exposed infants that showed more optimal neurobehavioral function with increasing time since birth. Further research examining the effects of prenatal opioid exposure on the developing brain, not just at birth but over the longer term, will be important in understanding the potential neuropathological mechanisms underlying these early neurobehavioral observations.
Our findings that a discrete profile of neurobehavior could be identified that showed the most extreme negative scores on the NNNS and was associated with poorer clinical and neuro-developmental outcomes later in infancy is consistent with the findings of Liu et al. [51]. They found the most negative pattern of neurobehavior was associated with a group of children who were prenatally exposed to cocaine plus opiates, tobacco and marijuana. Children in this group compared to the other profiles were more likely to be born preterm, weigh less at birth, and more likely to have an abnormal ultrasound reading at 1 month. Over the first 4 years of life, nearly 40% had clinically significant behavior and school readiness problems, and approximately 35% had a low IQ.

These findings highlight a unique profile of children that appear to be at particularly high neurodevelopmental risk. They also suggest the possibility of early detection of these infants prior to hospital discharge using existing medical and family information alongside systematic and careful neurobehavioral evaluation of the infant. Detecting specific neurobehavioral deficits early in the postnatal period that are associated with poorer neurodevelopmental outcomes later in childhood could also inform the development of intervention programs targeted to those exhibiting these deficits. Finally, these data do raise serious concerns about the longer-term health and neurodevelopment of these children, especially since many are likely to be discharged into challenging home circumstances characterized by social adversity, maternal mental illness and ongoing parental psychoactive drug use [60]. Thus, further longer term follow-up studies will also be important, both in terms of assessing the predictive utility of neurobehavioral observations and clarifying the longer-term developmental and psychosocial needs of these children and their families [61].

Acknowledgments
The authors are grateful to Alison Gray, Carole Spencer, Kirsty Donaldson, and Jacqui Knight for assistance with sample recruitment/retention and data collection. Most importantly, we would like to thank the families who kindly gave their time and support to this study.

Author Contributions
Conceptualization: Trecia A. Wouldes, Lianne J. Woodward.
Formal analysis: Trecia A. Wouldes.
Funding acquisition: Trecia A. Wouldes, Lianne J. Woodward.
Methodology: Trecia A. Wouldes, Lianne J. Woodward.
Project administration: Lianne J. Woodward.
Writing – original draft: Trecia A. Wouldes.
Writing – review & editing: Lianne J. Woodward.

References
1. United Nations Office on Drugs and Crime. World Drug Report. 2017.
2. Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses-a US epidemic. Morbidity and Mortality Weekly Report. 2012; 61(1):10. PMID: 22237030
3. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. The New England Journal of Medicine. 2016; 374:154–63. https://doi.org/10.1056/NEJMc1508490 PMID: 26760086
4. Salihu HM, Mogos MF, Saíninas-Miranda AA, Salemi JL, Whiteman VE. National trends in maternal use of opioid drugs among pregnancy-related hospitalizations in the United States, 1998 to 2009. Am J Perinatol. 2015; 32:289–98. https://doi.org/10.1055/s-0034-1384642 PMID: 25077473
5. American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 1998; 101(6):1079–88.

6. Finnegan LP. Maternal and neonatal effects of drug dependence in pregnancy. In: Lowinson JH, Ruiz P, editors. Substance Abuse: Clinical Problems and Perspectives. Baltimore: Williams & Williams; 1981.

7. Harper RG, Solish GI, Purow HM, Sang E, Panepinto WC. The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants. Pediatrics. 1974; 54(3).

8. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. Clin Pediatr (Phila). 1975; 14(6):592–4.

9. Chasnoff IJ, Burns WJ. The Moro reaction: A scoring system for neonatal narcotic withdrawal. Dev Med Child Neurol. 1984; 26:484–9. https://doi.org/10.1111/j.1469-8749.1984.tb04475.x PMID: 6479468

10. Sanlorenzo LA, Stark AR, Patrick SW. Neonatal abstinence syndrome: an update. Curr Opin Pediatr. 2018; 30(2):182–6. https://doi.org/10.1097/MOP.0000000000000589 PMID: 29346142

11. Winkelman TNA, Villapiano N, Kozihamnn KB, Davis MM, Patrick SW. Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004–2013. Pediatrics. 2014; 134(4):e20173520.

12. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. Neonatal ICUs. The New England Journal of Medicine. 2015; 372(22):2118–26. https://doi.org/10.1056/NEJMsa1500439 PMID: 25913111

13. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug & Alcohol Dependence. 2005; 79(1):1–10.

14. Finnegan LP. Management of pregnant drug-dependent women. Annals New York Academy of Sciences. 1978; 311:136–46.

15. Gottheil E, Sterling RC, Weinstein SP. Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis. 1993; 12(4):45–57. https://doi.org/10.1300/J069v12n04_04 PMID: 8292639

16. Bellis DJ. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: effects of free methadone maintenance. J Addict Dis. 1993; 12(1):7–23. https://doi.org/10.1300/J069v12n01_02 PMID: 8391030

17. Brogley SB, Saia KA, Walley AY, Du HM, Sebastiari P. Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. Am J Epidemiol. 2014; 180(7):673–86. https://doi.org/10.1093/aje/kwu190 PMID: 25152072

18. Wouldest TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2013; 35(3):406–13. https://doi.org/10.1016/j.ntt.2012.07.007 PMID: 23092336

19. Jones HE, Finnegn LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012; 72(6):747–57. https://doi.org/10.2165/11632820-000000000-00000 PMID: 22512363

20. ACOG Committee Opinion. Opioid use and opioid use disorder in pregnancy. Committee opinion No. 711. The American College of Obstetricians and Gynecologists. 2017; 711:61–94.

21. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database of Systematic Reviews. 2013;CD006318(12). https://doi.org/10.1002/14651858.CD006318.pub3 PMID: 24366859

22. Friedman MA, Spitzer AR. Discharge criteria for the term newborn. Pediatr Clin North Am. 2004; 51:599–618. https://doi.org/10.1016/j.pcl.2004.01.011 PMID: 15175787

23. Soule AB, Standley K, Copans SA, Davis M. Clinical uses of the Brazelton Neonatal Scale. Pediatrics. 1974; 54:583–6. PMID: 4453456

24. Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012; 107 Suppl 1:45–52.

25. Salisbury AL, Coyle MG, O'Grady KE, Heil SH, Martin PR, Stine SM, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. 2012; 107 Suppl 1:36–44.
28. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates. Addiction. 2012; 107(S1):53–62.

29. Coyle MG, Salisbury AL, Lester B, Jones HE, Lin H, Graf-Rohrmeister K, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012; 107(Suppl. 1):63–73.

30. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012; 107 Suppl 1:5–27.

31. Velez ML, Jansson LM, Schroeder JR, Williams E. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res. 2009; 66(6):704–9. https://doi.org/10.1203/PDR.0b013e3181bc035d PMID: 19690513

32. Heller NA, Logan BA, Morrison DG, Paul JA, Brown MS, Hayes MJ. Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal. Developmental Psychobiology. 2017; 59:574–82. https://doi.org/10.1002/dev.21532 PMID: 28561904

33. Lester BM, Tronick EZ. The Neonatal Intensive Care Unit Neurobehavioral Scale (NNNS). Pediatrics. 2004; 113(Supplement):631–99.

34. Tronick EZ, Olson K, Rosenberg R, Bohne L, Liu J, Lester BM. Normative neurobehavioral performance of healthy infants on the Neonatal Intensive Care Unit Neurobehavioral Scale. Pediatrics. 2004; 113:676–8. PMID: 14993526

35. Chasnoff IJ, Burns KA, Burns WJ, Schnoll SH. Prenatal drug exposure: Effects on neonatal and infant growth and development. Neurobehavioral Teratol. 1986; 8:357–62. PMID: 3762846

36. Johnson HL, Diano A, Rosen TS. 24-Month neurobehavioral follow-up of children of methadone-maintained mothers. Infant Behavior and Development. 1984; 7:115–23.

37. Kaltenbach K, Graziani L, Finnegan LP. Methadone exposure in utero: Developmental status at one and two years of age. Pharmacol Biochem Behav. 1979; Supplement 11:15–7.

38. Rosen TS, Johnson HL. Children of methadone-maintained mothers: Follow-up to 18 months of age. The Journal of Pediatrics. 1982; 101:192–6. https://doi.org/10.1016/s0022-3476(82)80115-7 PMID: 6178811

39. Rosen TS, Johnson HL. Drug-addicted mothers, their infants, and SIDS. Annals New York Academy of Sciences. 1988; 535:89–95.

40. Hans SL. Developmental consequences of prenatal exposure to methadone. Annals New York Academy of Sciences. 1989; 562:195–207.

41. Wilson GS. Clinical studies of infants and children exposed perinatally to heroin. Annals New York Academy of Sciences. 1989; 562:183–94.

42. Bayley N. Manual for the Bayley Scales of Infant Development. New York: Psychological Corporation; 1969.

43. Conradt E, Flannery T, Aschner JL, Annett RD, Croen LA, Duarte CS, et al. Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities. Pediatrics. 2019; 144(3):09.

44. Messinger DS, Bauer CR, Das A, Seifer R, Lester BM, Lagasse LL, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics. 2004; 113(6):1677–85. https://doi.org/10.1542/peds.113.6.1677 PMID: 15173491

45. Bunikowski R, Grimmert I, Heise A, Metze B, Schafer A, Obladen M. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr. 1998; 157(9):724–30. https://doi.org/10.1007/s004310050923 PMID: 9776530

46. McGlone L, Macler H. Infants of opioid-dependent mothers: neurodevelopment at six months. Early Hum Dev. 2015; 91(1):19–21. https://doi.org/10.1016/j.earhumdev.2014.10.006 PMID: 25460252

47. Konijnenberg C, Sarfi M, Melinder A. Mother-child interaction and cognitive development in children prenatally exposed to methadone or buprenorphine. Early Hum Dev. 2016; 101:91–7. https://doi.org/10.1016/j.earhumdev.2016.08.013 PMID: 27614330

48. van Baar A, Soepatmi S, Gunning WB, Akkerhuis GW. Development after prenatal exposure to cocaine, heroin and methadone. Acta Paediatrica Supplement. 1994; 404:40–6.

49. Muthen B, Muthen LK. Integrating person-centered and variable-centered analyses: Growth mixture modeling with latent trajectory classes. Alcoholism: Clinical and Experimental Research. 2000; 24(6):882–91.

50. Goodman LA. Exploratory latent structure analysis using both identifiable and unidentifiable models. Biometrika. 1974; 61(2):215–31.
51. Liu J, Bann C, Lester B, Tronick E, Das A, Lagasse L, et al. Neonatal neurobehavior predicts medical and behavioral outcome. Pediatrics. 2010; 125(1):e90–8. https://doi.org/10.1542/peds.2009-0204 PMID: 19969621

52. Davie-Gray A, Moor S, Spencer C, Woodward LJ. Psychosocial characteristics and poly-drug use of pregnant women enrolled in methadone maintenance treatment. Neurotoxicol Teratol. 2013; 38:46–52. https://doi.org/10.1016/j.ntt.2013.04.006 PMID: 23639593

53. World Health Organization. Composite International Diagnostic Interview (CIDI). 1.1 ed. Geneva: World Health Organization; 1993.

54. Lester BM. The Maternal Lifestyles Study. Annals of the New York Academy of Sciences. 1998; 846:296–305.

55. Bayley N. Training Manual for the Bayley Scales of Infant Development, 2nd ed. San Antonio, TX: The Psychological Corporation; 1993.

56. Laursen B, Little TD, Card NA. Handbook of Developmental Research Methods. New York:NY: The Guilford Press; 2012.

57. Muthen LK, Muthen BO. Mplus User’s Guide. Eighth Edition. Los Angeles, CA: Muthen & Muthen; 1998–2017.

58. Sucharew H, Khoury JC, Xu Y, Succop P, Yolton K. NICU Network Neurobehavioral Scale profiles predict developmental outcomes in a low-risk sample. Paediatr Perinat Epidemiol. 2012; 26:344–52. https://doi.org/10.1111/j.1365-3016.2012.01288.x PMID: 22686386

59. Nylund KL, Asparouhov T, Muthen BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. Structural Equation Modeling: A Multidisciplinary Journal. 2007; 14(4):535–69.

60. Levine TA, Woodward LJ. Early inhibitory control and working memory abilities of children prenatally exposed to methadone. Early Hum Dev. 2018; 116:68–75. https://doi.org/10.1016/j.earlhumdev.2017.11.010 PMID: 29195088

61. Larson JJ, Graham DL, Singer LT, Beckwith AM, Terplan M, Davis JM, et al. Cognitive and Behavioral Impact on Children Exposed to Opioids During Pregnancy. Pediatrics. 2019; 18:18.